PDZ and LIM domain protein 4 (PDLIM4)

PDZ and LIM domain protein 4 (PDLIM4), also known as reversion-induced LIM protein (RIL), is an actin-associated adaptor protein belonging to the PDLIM family, characterized by a single N-terminal PDZ domain and a single C-terminal LIM domain[2][3][4]. PDLIM4 participates in the organization of the actin cytoskeleton, promotes the formation of actin stress fibers, and interacts directly with α-actinin and other cytoskeletal elements[2][3][4]. In neurons, it regulates the trafficking and membrane localization of AMPA-type glutamate receptors, contributing to synaptic plasticity[2][3]. Through scaffolding and adaptor functions, PDLIM4 links cytosolic and membrane proteins to the actin cytoskeleton. This protein is widely expressed, with notable roles in muscle development and the central nervous system[1][2][3]. Human mutations or altered expression of PDLIM4 have been implicated in osteoporosis, reflecting its importance in bone biology[2]. There is no evidence that PDLIM4 is a direct therapeutic target or that there are drugs acting directly upon it[2][3].\n\nNotes:\n- PDLIM4 is not a classical "therapeutic target" such as a receptor, enzyme, transporter, or channel; it is a non-enzymatic protein scaffold involved in cytoskeletal regulation[2][3].\n- No FDA-approved drugs are known to interact directly with PDLIM4[2][3].\n- The protein's principal disease association is with osteoporosis, as a genetic factor influencing bone mineral density[2].\n- Although it is sometimes discussed in the context of cancer biology and signaling (e.g., SRC inactivation), it has not been validated as a drug target or clinical biomarker[2][3].

Other names

Reversion-induced LIM proteinLIM protein RILRILEnigma homolog